Date: 2011-12-07
Type of information: Collaboration agreement
Compound: PredictMDx™
Company: MDxHealth (Belgium) University Hospital of Bonn (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease: glioblastoma
Details: MDxHealth has entered into a companion diagnostic agreement with Prof. Dr. Ulrich Herrlinger of the Division of Clinical Neuro-oncology of the University Hospital of Bonn (Germany) to provide MGMT epigenetic testing. MDxHealth’s epigenetic MGMT test (PredictMDx™ for Glioblastoma) will be used to select patients to enroll in a randomized, multicenter phase III clinical study examining the addition of lomustine (also known as CCNU) to the current therapy of temozolomide/radiotherapy in MGMT methylated, newly diagnosed glioblastoma multiforme (GBM) patients, a severe form of brain cancer. The study, called CeTeG, will start recruiting patients this month and will last for approximately 2 years.
Financial terms: Financial terms of the deal were not disclosed.
Latest news:
